References
- 1. Gormsen L, Rosenberg R, Bach FW, Jensen TS: Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain 2010, 14:127.e1-8.
- 2. Munro G, Ahring PK, Mirza NR: Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009, 30:453-9.
- 3. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU: Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009, 141:233-8.
- 4. Malan TP, Mata HP, Porreca F: Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology 2002, 96:1161-7.
- 5. Casarrubea M, Sorbera F, Santangelo A, Crescimanno G: The effects of diazepam on the behavioral structure of the rat’s response to pain in the hot-plate test: anxiolysis vs. pain modulation. Neuropharmacology 2012, 63:310-21.
- 6. Stahl SM: Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002, 63:756-7.
- 7. Sieghart W, Ernst M: Heterogeneity of GABAA receptors: revived interest in the development of subtype-selective drugs. Curr Med Chem - Central Nervous System Agents 2005, 5:217-242.
- 8. Auta J, Kadriu B, Giusti P, Costa E, Guidotti A. Anticonvulsant, anxiolytic, and non- sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacol Biochem Behav 2010, 95:383-9.
- 9. Rabe H, Kronbach C, Rundfeldt C, Lüddens H: The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam. Neuropharmacology 2007, 52:796-801.
- 10. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H: Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999, 401:796-800.
- 11. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000, 3:587-92.
- 12. Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, et al: Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008, 451:330-4.13.
- 13. Cook JM, Huang S, Sarma PVVS, Zhang C, Zhou H; Wisys Technology Found Inc, James M Cook, Hao Zhou, Shengming Huang, P V V S Sarma, Chunchun Zhang, assignee. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedativehypnotic and ataxic effects. United States patent US WO2006004945 A1 2006 Jan 12. [http://patentscope.wipo.int/search/en/WO2006004945]
- 14. Drexler B, Zinser S, Huang S, Poe MM, Rudolph U, Cook JM, Antkowiak B: Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states. Eur J Pharmacology 2013, 5:703.
- 15. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA: A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 2011, 36:1903-11.
- 16. Bridge PM, Ball DJ, Mackinnon SE, Nakao Y, Brandt K, Hunter DA, et al: Nerve crush injuries--a model for axonotmesis. Exp Neurol 1994, 127:284-90.
- 17. Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, et al: Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology 2008, 33:332-9.
- 18. Savić MM, Majumder S, Huang S, Edwankar RV, Furtmüller R, Joksimović S, et al: Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats? Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:376-86.
- 19. Savić MM, Obradović DI, Ugresić ND, Cook JM, Yin W, Bokonjić DR: Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav 2004, 79:279-90.
- 20. Dworkin RH: An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002, 18:343-9.
- 21. Finnerup NB, Sindrup SH, Jensen TS: The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-81.
- 22. O’Connor AB, Dworkin RH: Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009, 122:S22-32.
- 23. Ellis A, Bennett DL: Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 2013, 111:26-37.
- 24. Naik AK, Latham JR, Obradovic A, Jevtovic-Todorovic V: Dorsal root ganglion application of muscimol prevents hyperalgesia and stimulates myelin protein expression after sciatic nerve injury in rats. Anesth Analg 2012, 114:674-82.
- 25. Huston JP, Schulz D, Topic B: Toward an animal model of extinction-induced despair: focus on aging and physiological indices. J Neural Transm 2009, 116:1029-36.
- 26. Ryan CG, Gray HG, Newton M, Granat MH: The relationship between psychological distress and free-living physical activity in individuals with chronic low back pain. Man Ther 2010, 15:185-9.
- 27. Divljaković J, Milić M, Timić T, Savić MM: Tolerance liability of diazepam is dependent on the dose used for protracted treatment. Pharmacol Rep 2012, 64:1116-25.
- 28. Friedman H, Abernethy DR, Greenblatt DJ, Shader RI: The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. Psychopharmacology 1986, 88:267-70.
- 29. Samardžić J, Puškaš L, Obradović M, Lazić-Puškaš D, Obradović D: Antidepressant effects of an inverse agonist selective for α5 GABA-A receptors in the rat forced swim test, Acta Vet (Beograd) 2014, 64(1):52-60.